Perspectives for Clinical Translation of Adipose Stromal/Stem Cells

Table 3

Marketing authorisation approved advanced therapy medicinal products, classified as cell therapy medicinal products or tissue-engineered products, in Europe in October 2018.

Product name	Developer	Active substance	Indication	Approval	Status
Alofisel	TiGenix	Ex vivo expanded human allogeneic ASCs	Perianal fistulas in Crohn’s disease	2018	Approved
Spherox	CO.DON	Spheroids of human autologous matrix-associated chondrocytes	Cartilage defects in the knee	2017	Approved
Zalmoxis	MolMed	Genetically modified human allogeneic T cells	Stem cell transplantation in high-risk blood cancer	2016	Approved
Holoclar	Chiesi	Ex vivo expanded autologous corneal epithelial cells containing stem cells	Severe limbal stem cell deficiency in the eye	2015	Approved
Provenge	Dendreon	Autologous peripheral blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor	Metastatic prostate cancer	2013	Withdrawn in 2015
MACI	Vericel	Matrix-applied autologous cultured chondrocytes	Cartilage defects in the knee	2013	Withdrawn in 2014
Chondrocelect	TiGenix	Ex vivo expanded autologous cartilage cells expressing specific marker proteins	Cartilage defects	2009	Withdrawn in 2016